About PI-88: PI-88 belongs to a new class of multi-targeted cytostatic cancer therapeutics.
The study will recruit approximately 600 patients at 65-70 hospitals in more than a dozen countries. Disease-free survival is the primary endpoint of the study. After completing this study the results are expected to of global of global regulatory filings for PI-88.. About PI-88: PI-88 belongs to a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first – in-class mechanism as heparan sulfate mimetic. Angiogenesis and metastasis – critical to the growth and progression of cancer its anti-tumor activity is based on inhibition of two biological processes. In this disease setting Orphan Drug Designation from the European Medicines Evaluation Agency and Fast Track designation by the United States Food and Drug Administration approval.
Progen has operations in Australia and the USA.. PATHWAY, a double-blinded, placebo-controlled study was designed to establish the efficacy and safety of PI-88 in post – resection liver cancer setting. Recruit approximately 600 patients at about 65-70 hospitals in more than a dozen countries. Disease free survival, a measure of the average length of time that the patient remain relapse recurrence, the primary endpoint. After completing this study , the results are expected to form the basis of global registration filings for PI-88.S. FDA Fast Track and EU EMEA underlines its underlines its dedication our commitment to fast for this important drug available to patients who currently have few treatment options available.Medical intelligence was used to modify risk in particular areas where the wire has been to be absent reported to. Of the human risk population under each levels of transferring was then adapted to by combining the categoric risk map with a high-resolution population of surface to 2009 and a global on map Duffy negativeness prevalence obtained. Duffy negativeness be the absence of Duffy blood group antigen in red blood cells, which helpful in partial protection of against infection with P. Vivax. And yet how Duffy negativity of prevalence in the population indicates greater protection against P.
ItemCITATION: Guerra CA, Howes RE, Patil Reg., Gething PW, Van Boeckel TP, The international limits and populations at risk of Plasmodium vivax transmission in 2009. PLoS Negl drops Dis 4 : e774. Doi: 10.1371/journal.